NCT01730833
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Central nervous system metastases
https://ClinicalTrials.gov/show/NCT01730833